AlphaFold-class platforms have graduated from breakthrough science to a fast-moving business segment worth about US $5 billion in pharma deals since 2022. With DeepMind's release of AlphaFold 3, organizations must decide whether to build, partner, or subscribe before Alphabet's paid enterprise API arrives in 2025.